摘要
目的:评价自体造血干细胞移植(AHSCT)治疗恶性淋巴瘤患者的疗效。方法:采用AHSCT治疗恶性淋巴瘤患者15例,其中霍奇金淋巴瘤患者3例(均为复发病例),非霍奇金淋巴瘤患者12例(Ⅲ、Ⅳ期或复发病例,IPI评分2-4分)。采集外周血造血干细胞前均经化疗及动员剂动员(CHOP方案9例,CHOP+MTX 3例,CEP、大剂量MTX、单用G-CSF各1例)。预处理方案为联合化疗10例(BEAC、CBV方案为主),联合化疗加放射治疗5例(TBI、TLI各1例,提前局部照射3例)。结果:移植后白细胞≥1.0×109/L的中位时间为10(9-13)天,血小板≥50×109/L的中位时间为14(11-17)天。随访时间为1-110.5个月。中位生存时间为43(1-110.5个月)个月,3年总生存率(OS)为66.7%。结论:AHSCT是一种治疗复发难治恶性淋巴瘤的安全有效的方法。
Objective：To investigate the effects of treatment of malignant lymphoma by autologous hematopoietic stem cell transplantation（AHSCT）.Methods：All 15 patients with malignant lymphoma received AHSCT,including 3 patients with HL and 12 patients with NHL of relapse or late stage.Before transplantation,chemotherapy with G-CSF（n=1）,chemotherapy with CHOP（n=9）,chemotherapy with CHOP and MTX（n=3）,chemotherapy with CEP（n=1） or chemotherapy with high-dose MTX.10 patients received combined chemotherapy while the other five patients received high-dose chemotherapy with radiotherapy.Results：Median（range） time for the recovery of WBC ≥1.0×109/L,and platelets ≥50×109/L were 10（9-13） days and 14（11-17） days respectively.After a follow-up time of 1-110.5 months,the median survival time was 43（1-110.5） months,the estimated 3-year overall survival（OS） rate was 66.7 %.Conclusion：AHSCT is safe and efficacious in patients with relapse or refractory malignant lymphoma.
出处
《现代肿瘤医学》
CAS
2013年第6期1330-1332,共3页
Journal of Modern Oncology
关键词
自体造血干细胞移植
淋巴瘤
疗效
autologous hematopoietic stem cell transplantation
lymphoma
efficacy
